Interval cancers in prostate cancer screening: Comparing 2- and 4-year screening intervals in the European randomized study of screening for prostate cancer, Gothenburg and Rotterdam

Journal of the National Cancer Institute

Volumn 99, Issue 17, 2007, Pages 1296-1303

  Roobol, Monique J ^a   Grenabo, Anna ^b   Schröder, Fritz H ^a   Hugosson, Jonas ^b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANTIGEN DETECTION; ARTICLE; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER MORTALITY; CANCER SCREENING; CANCER STAGING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; EUROPE; FOLLOW UP; GLEASON SCORE; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL;

AGED; HUMANS; INCIDENCE; MALE; MASS SCREENING; MIDDLE AGED; NETHERLANDS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REPRODUCIBILITY OF RESULTS; SWEDEN; TIME FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 34548581216     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djm101     Document Type: Article

References (35)

1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30.
2. Jones GW, Mettlin C, Murphy GP, Guinan P, Herr HW, Hussey DH, et al. Patterns of care for carcinoma of the prostate gland: Results of a national survey of 1984 and 1990. J Am Coll Surg 1995;180:545-54.
3. Draisma G, Boer R, Otto SJ, van der Cruijsen-Koeter IW, Damhuis RA, Schröder FH, et al. Lead times and overdetection due to prostate-specific antigen screening: Estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 2003; 95:868-78.
4. Sennfalt K, Sandblom G, Carlsson P, Varenhorst E. Costs and effects of prostate cancer screening in Sweden - a 15-year follow-up of a randomized trial. Scand J Urol Nephrol 2004;38:291-8.
5. Roobol MJ, Schröder FH. European Randomized Study of Screening for Prostate Cancer: Achievements and presentation. BJU Int 2003;92 Suppl 2:117-22.
6. Schröder FH, Damhuis RA, Kirkels WJ, De Koning HJ, Kranse R, Nijs HG, et al. European Randomized Study of Screening for Prostate Cancer - the Rotterdam pilot studies. Int J Cancer 1996;65:145-51.
7. Schröder FH, Roobol MJ, Damhuis RA, de Koning HJ, Blijenberg BG, van der Kwast TH, et al. Rotterdam randomized pilot studies of screening for prostate cancer - an overview after 10 years. J Natl Cancer Inst 2005;97:696.
8. Roobol MJ, Kirkels WJ, Schröder FH. Features and preliminary results of the Dutch centre of the ERSPC (Rotterdam, The Netherlands). BJU Int 2003;92 Suppl 2:48-54.
9. Hugosson J, Aus G, Lilja H, Lodding P, Pihl CG. Results of a randomized, population-based study of biennial screening using serum prostate-specific antigen measurement to detect prostate carcinoma. Cancer 2004; 100:1397-405.
10. Eskew LA, Bare RL, McCullough DL. Systematic 5 region prostate biopsy is superior to sextant method for diagnosing carcinoma of the prostate. J Urol 1997;157:199-202.
11. Schröder FH, Hermanek P, Denis L, Fair WR, Gospodarowicz MK, Pavone-Macaluso M. The TNM classification of prostate cancer. Prostate Suppl 1992;4:129-38.
12. Gleason DF, Mellinger GT. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 1974;111:58-64.
13. Ciatto S. The ERSPC Quality Control Committee. BJU Int 2003;92 Suppl 2:57-61.
14. Aus G, Bergdahl S, Lodding P, Lilja H, Hugosson J. Prostate cancer screening decreases the absolute risk of being diagnosed with advanced prostate cancer-results from a prospective, population-based randomized controlled trial. Eur Urol 2007;51:659-64.
15. Otto SJ, Schröder FH, de Koning HJ. Low all-cause mortality in the volunteer-based Rotterdam section of the European Randomised Study of Screening for Prostate Cancer: Self-selection bias? J Med Screen 2004;11: 89-92.
16. Wang H, Bjurstam N, Bjorndal H, Braaten A, Eriksen L, Skaane P, et al. Interval cancers in the Norwegian breast cancer screening program: frequency, characteristics and use of HRT. Int J Cancer 2001;94:594-8.
17. Fraucheboud J, de Koning HJ, Beemsterboer PM, Boer R, Verbeek AL, Hendriks JH, et al. Interval cancers in the Dutch breast cancer screening programme. Br J Cancer 1999;81:912-7.
18. Beemsterboer PM, de Koning HJ, Kranse R, Trienekens PH, van der Maas PJ, Schröder FH. Prostate specific antigen testing and digital rectal examination before and during a randomized trial of screening for prostate cancer: European Randomized Study of Screening for Prostate Cancer, Rotterdam. J Urol 2000;164:1216-20.
19. Otto SJ, van der Cruijsen-Koeter IW, Liem MK, Korfage IJ, Lous JJ, Schröder FH, et al. Effective PSA contamination in the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer. Int J Cancer 2003;105:394-9.
20. Hugosson J, Aus G, Lilja H, Lodding P, Pihl CG, Pileblad E. Prostate specific antigen based biennial screening is sufficient to detect almost all prostate cancers while still curable. J Urol 2003;169:1720-3.
21. van der Cruijsen-Koeter IW, Vis AN, Roobol MJ, Wildhagen MF, de Koning HJ, van der Kwast TH, et al. Comparison of screen detected and clinically diagnosed prostate cancer in the European randomized study of screening for prostate cancer, section Rotterdam. J Urol 2005;174:121-5.
22. Regionalt Onkologiskt Centrum i Uppsala/Örebroregionen. Available at: www.roc.se. [Last accessed: May 30, 2007.]
23. Centraal Bureau voor de StatistiekAvailable at: www.cbs.nl. [Last accessed: May 30, 2007.]
24. Vis AN, Hoedemaeker RF, Roobol M, van der Kwast TH, Schröder FH. Tumor characteristics in screening for prostate cancer with and without rectal examination as an initial screening test at low PSA (0.0-3.9 ng/ml). Prostate 2001;47:252-61.
25. Gosselaar C, Roobol MJ, Roemeling S, de Vries SH, van der Cruijsen-Koeter IW, van der Kwast TH, et al. Screening for prostate cancer without digital rectal examination and transrectal ultrasound: results after four years in the European Randomized Study of Screening for Prostate Cancer (ERSPC), Rotterdam. Prostate 2006;66:625-31.
26. van der Cruijsen-Koeter IW, Roobol MJ, Wildhagen MF, van der Kwast TH, Kirkels WJ, Schröder FH. Tumor characteristics and prognostic factors in two subsequent screening rounds with 4-year interval within prostate cancer screening trial, ERSPC, Rotterdam. Urology 2006;68:615-20.
27. Carter HB, Epstein JI, Chan DW, Fozard JL, Pearson JD. Recommended prostate-specific antigen testing intervals for the detection of curable prostate cancer. JAMA 1997;277:1456-60.
28. Ito K, Yamamoto T, Ohi M, Takechi H, Kurokawa K, Suzuki K, et al. Natural history of PSA increase with and without prostate cancer. Urology 2003;62:64-9.
29. Ito K, Yamamoto T, Ohi M, Takechi H, Kurokawa K, Suzuki K, et al. Possibility of rescreening intervals of more than one year in men with PSA levels of 4.0 ng/ml or less. Prostate 2003;57:8-13.
30. Aus G, Damber J-E, Khatami A, Lilja H, Stranne J, Hugosson J. Individualized screening interval for prostate cancer based on prostate-specific antigen level. Arch Intern Med 2005;165:1857-61.
31. Schröder FH, Raaijmakers R, Postma R, van der Kwast TH, Roobol MJ. 4-year prostate specific antigen progression and diagnosis of prostate cancer in the European Randomized Study of Screening for Prostate Cancer, Rotterdam. J Urol 2005;174:489-94.
32. Roobol MJ, Roobol DW, Schröder FH. Is additional testing necessary in men with prostate-specific antigen levels of 1.0 ng/ml or less in a population based screening setting? (ERSPC, section Rotterdam). Urology 2005;65:343-6.
33. Draisma G, Boer R, Otto SJ, van der Cruijsen-Koeter IW, Damhuis RA, Schröder FH, et al. Lead times and over detection due to prostate-specific antigen screening: Estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 2003;95:868-78.
34. Steyerberg EW, Roobol MJ, Kattan MW, van der Kwast TH, de Koning HJ, Schröder FH. Prediction of indolent prostate cancer: Validation and updating of a prognostic nomogram. J Urol 2007;177:107-12; discussion 112.
35. Roobol MJ, Schröder FH, Kranse R; ERSPC, Rotterdam. A comparison of first and repeat (four years later) prostate cancer screening in a randomized cohort of a symptomatic men aged 55-75 years using a biopsy indication of 3.0 ng/ml (results of ERSPC, Rotterdam). Prostate 2006;66:604-12.